Abstract

Stryker will report its second-quarter 2026 results on July 30, 2026, Post Market, with investor attention centered on revenue growth near 10.95%, margin progression versus last quarter, and whether adjusted EPS trends align with the anticipated improvement to around $3.49.

Market Forecast

Market expectations point to a constructive quarter for Stryker, with current-quarter revenue estimated at 6.58 billion US dollars, implying 10.95% year-over-year growth, and adjusted EPS forecast at 3.49, up 13.67% year-over-year; consensus EBIT is expected at 1.70 billion US dollars, up 13.28% year-over-year. There is no widely disseminated forecast for gross profit margin or net profit margin for this quarter, though investors will look for sequential stability relative to recent levels. The main business mix skews toward surgical and neurotechnology alongside orthopaedics, with a focus on capital equipment and enabling technologies that support procedure growth and product pull-through across hospitals and ambulatory surgical centers. The most promising near-term growth area cited by institutions is orthopaedics enabling technologies and robotics, anchored by the Mako ecosystem; last quarter, orthopaedics contributed 2.81 billion US dollars, while med/surg and neurotechnology delivered 3.21 billion US dollars, highlighting the scale to drive operating leverage as utilization trends normalize.

Last Quarter Review

In the prior quarter, Stryker generated 6.02 billion US dollars of revenue, reported a gross profit margin of 63.55% and a net profit margin of 12.38%, delivered GAAP net profit attributable to the parent company of 745.00 million US dollars, and posted adjusted EPS of 2.60, down 8.45% year-over-year. A key financial highlight was the firm’s ability to sustain high-60% gross margin dynamics even as adjusted EPS dipped year-over-year, reflecting disciplined pricing and mix while absorbing operating investments and transition costs. Main business highlights show med/surg and neurotechnology revenue of 3.21 billion US dollars and orthopaedics revenue of 2.81 billion US dollars; segment-level year-over-year changes were not disclosed, but the scale of each franchise underscores the breadth of growth catalysts across capital equipment, implants, and enabling technologies.

Current Quarter Outlook

MedSurg and Neurotechnology: execution on installed-base leverage and product refresh

This quarter’s narrative for med/surg and neurotechnology revolves around execution on a large installed base and product refresh cycles that support procedure volumes and consumable uptake. Attention will be on adoption traction for newly launched platforms and accessories that can drive better utilization, including updates in power tools and navigation, and any contribution from the recently introduced TPXHD small-bone power system that emphasizes torque and speed improvements in revision procedures. The business is well placed to translate clinical demand into recurring revenue from disposables, service contracts, and upgrades; watch commentary on utilization rates across US hospitals and ambulatory sites because mixed signals from hospital operators have periodically pressured sentiment. Hospital capital budgets remain a swing factor for large-ticket equipment orders, and management color on quote and backlog conversion will help investors gauge the durability of med/surg growth into the second half. Even without a formal gross-margin guide for the quarter, mix within med/surg and neurotechnology should matter for consolidated margin; higher service intensity and premium-priced devices tend to support gross profit margin, while any incremental freight or component cost normalization could offer a modest tailwind. With consensus revenue at 6.58 billion US dollars and EBIT expected to grow by 13.28% year-over-year, the setup assumes healthy contribution from this franchise; any incremental confirmation of stronger capital placement or service attach would likely be viewed favorably.

Orthopaedics and the Mako platform: momentum from robotics expansion and implant mix

For orthopaedics, the core debate centers on whether procedure momentum and robotics expansion can translate into volume and mix benefits that support both growth and profitability. Institutions are watching the commercial rollout of Mako RPS for total knee arthroplasty in the United States, which is designed to lower adoption barriers for surgeons familiar with manual techniques by offering a handheld robotic workflow integrated with Stryker’s Triathlon knee system and Q Guidance. A broader Mako footprint tends to correlate with premium implant pull-through and procedure standardization, which can raise average selling prices and improve predictability of demand. Orthopaedics contributed 2.81 billion US dollars last quarter and remains a critical revenue and earnings engine; a supportive environment for elective and outpatient procedures can amplify this contribution. Commentary around case growth, backlog normalization, and staffing constraints at provider sites will be closely parsed, especially after sector volatility linked to hospital updates in mid-July that weighed on medical device shares. If surgeon utilization remains resilient and the robotics-enabled mix keeps expanding, the consensus path to a 13.67% year-over-year rise in adjusted EPS appears attainable, with upside potential if pricing and case complexity skew favorable.

Pricing, mix, and margin dynamics: watch gross profit stability and operating leverage

The last-reported gross profit margin of 63.55% establishes a benchmark for investors to judge sequential progress this quarter. Mix will be key: a higher proportion of enabling technologies, advanced instruments, and premium implants generally supports margins, while a tilt toward lower-margin hardware or temporary pricing concessions can weigh on the percentage. Freight, logistics, and component availability have been gradually improving across the sector; any incremental benefit here could help stabilize cost of goods and underpin gross profit. Operating leverage should come into focus given that consensus projects EBIT growth of 13.28% year-over-year on revenue growth of 10.95%. If sales land near or above 6.58 billion US dollars and R&D and SG&A remain aligned with productivity improvements and incentive accruals, EBIT expansion can track or exceed revenue growth. Conversely, any transient costs from product introductions, integration of newly acquired technologies in peripheral vascular, or quality actions can modestly pressure margins; investors will scrutinize management’s commentary on the cadence of spending and timing of efficiency gains to gauge the trajectory into the second half.

What could move the stock around the print: revenue quality, EPS conversion, and updates on portfolio catalysts

Stryker shares are likely to respond to the quality of revenue versus the headline number—investors will differentiate between organic growth, price/mix, and one-off items. EPS conversion relative to revenue will be watched alongside flow-through to EBIT, given consensus for adjusted EPS of 3.49 and EBIT of 1.70 billion US dollars. A clean beat on margins or a constructive update on order momentum for capital platforms could support a positive reaction, while any sign of slower capital conversion or uneven utilization trends may cap upside even if revenue meets expectations. Product- and portfolio-specific updates can also move the narrative. Mako RPS adoption metrics, surgeon feedback, and any early evidence of expanding addressable workflows would be incremental positives, especially if tied to higher knee volumes or ASPs. In peripheral interventions and neurovascular, investors will listen for progress integrating new technologies acquired earlier in the year and for commentary on any ongoing quality actions; management framing around the scope, remediation, and commercial impact will be important to calibrate risk. On balance, the market setup leans toward a constructive print if management demonstrates steady execution on growth vectors and signals confidence in second-half visibility.

Capital deployment and pipeline execution: reinforcing near- and medium-term growth

Beyond the quarter, the company’s capital allocation toward innovation and acquisitions plays into the earnings setup by shaping the cadence of new product launches and category expansion. The acquisition of technologies in peripheral vascular underscores a commitment to building breadth in high-need procedural categories; clarity on integration milestones, regulatory pathways, and commercialization timelines can help investors assess revenue contribution in late 2026 and 2027. In orthopaedics, continued enhancement of robotics workflows, navigation, and digital planning tools supports a virtuous cycle of utilization growth and implant economics; details on software updates and instrument compatibility can bolster confidence in sustained adoption. Commercial execution at ambulatory surgical centers and in international markets provides additional levers for growth. With prior-quarter adjusted EPS at 2.60 and consensus for the current quarter at 3.49, the implied step-up assumes healthy operating leverage; confirmation that pipeline launches and channel mix are tracking plan would validate the model. The interplay among new launches, recurring revenue attachment, and disciplined opex should remain central to margin progression through the back half of the year.

Analyst Opinions

Bullish opinions dominate among recently published views, with collected rating pieces skewing decisively positive: across the rating-focused items gathered, bullish calls outnumber bearish by a ratio of 6 to 0. Notable institutional voices include Citi’s Joanne Wuensch, who maintained a Buy rating with a 385 US dollars price target, and Bernstein’s Lee Hambright, who reiterated Buy with a 410 US dollars target, each emphasizing durable procedure demand and product-led growth. Canaccord Genuity reaffirmed Buy with a 435 US dollars target, highlighting continued expansion in enabling technologies, while Jefferies maintained Buy with a 465 US dollars target, reflecting confidence in orthopaedics momentum and the robotics roadmap. RBC Capital also reiterated Buy with a 435 US dollars target, underscoring the breadth of growth vectors across med/surg and neurotechnology, and BTIG maintained Buy with targets around 410–412 US dollars amid improving visibility into earnings power. Supplementary previews point to a constructive near-term setup: several institutions and market summaries cite consensus revenue of approximately 6.58 billion US dollars and adjusted EPS near 3.49, with EBIT projected around 1.70 billion US dollars, implying year-over-year growth outpacing revenue—an earnings quality profile that resonates with bullish theses. Additional coverage initiated or updated during the period, including BMO Capital’s Outperform and targets in the mid- to high-300s, and positive stances from Leerink and Argus, supports the view that innovation cadence and portfolio breadth are translating into consistent financial delivery. In analyzing the bullish case, institutions consistently point to three pillars. First, product innovation and platform expansion—particularly in robotics—are expected to support share capture and richer mix, enhancing revenue durability and margin potential. Second, a balanced business mix across capital equipment, implants, and consumables, coupled with an expanding installed base, fortifies recurring revenue streams, improving the predictability of cash flows and earnings. Third, execution on pipeline and capital deployment, including targeted M&A in vascular interventions and launches such as Mako RPS and TPXHD, provides incremental growth catalysts that can compound over several quarters. Bullish analysts acknowledge that sector volatility tied to hospital commentary and isolated quality actions can create short-term trading noise, but they argue these factors are manageable within the company’s broader operating model. For the upcoming print, the key validation points for the bullish narrative are in-line or better revenue, healthy EPS conversion toward the 3.49 mark, and constructive management commentary on adoption of new platforms and second-half momentum. Should these elements materialize, the majority view sees room for positive estimate revisions or multiple stabilization, aligning with the consensus expectation of revenue up 10.95% year-over-year and double-digit EBIT and EPS growth for the quarter.